MaxCyte Appoints Amanda L. Murphy as Chief Financial Officer and Names Ron Holtz as Senior Vice President & Chief Accounting Officer

Published on :

MaxCyte, Inc., a global cell-based therapies and life sciences company, announced today that Amanda L. Murphy, CFA, has joined the Company as Chief Financial Officer (CFO). Ron Holtz, who has served as MaxCyte’s CFO since 2005, will become Senior Vice President and Chief Accounting Officer (SVP & CAO).

5 Questions with Shruti Abbato, EVP, Business Development, CARMA Cellular Therapies at MaxCyte, Inc.

Published on :

Shruti has 20 years of business development experience in the biotechnology industry. She is currently responsible for building and growing MaxCyte’s CARMA Cell Therapies business. Before MaxCyte, she worked with Celdara Medical, Millendo, Medigene, Deciphera, and Human Genome Sciences. Shruti holds an MBA from the University of Pittsburgh and a BS in Chemical Engineering and Biochemistry from the University of Maryland.

The Story of Maryland’s Cell and Gene Therapy Cluster is Shared Loud and Clear at Inaugural Bio Innovation Conference

Published on :

The Story of Maryland’s Cell and Gene Therapy Cluster is Shared Loud and Clear at Inaugural Bio Innovation Conference October 8, 2019 On Monday morning in Bethesda, Maryland hundreds of [….]

MaxCyte Adds Vice President, Non-Clinical and Translational Studies, to Support Advancement of Programs from Its CARMA™ Platform

Dhana Chinnasamy, PhD
Published on :

MaxCyte Adds Vice President, Non-Clinical and Translational Studies, to Support Advancement of Programs from Its CARMA™ Platform Dhana Chinnasamy, PhD, will oversee non-clinical and translational activities for MaxCyte’s autologous cell [….]